

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

*Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting*  
January 9, 2023

**QUESTIONS**

---

---

1. **DISCUSSION:** Discuss how the studied use of aflibercept in the treatment of retinopathy of prematurity can best be communicated to physicians and the caregivers of these premature infants.
  
2. **DISCUSSION:** Discuss potential labeling including:
  - a. Wording of Indications and Usage
  - b. Wording of Warnings/Precautions
  - c. Wording of Dosing and Administration
  - d. Wording of Pediatric Use
  - e. Wording of the Clinical Trials section